DE60122928T2 - Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat - Google Patents
Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat Download PDFInfo
- Publication number
- DE60122928T2 DE60122928T2 DE60122928T DE60122928T DE60122928T2 DE 60122928 T2 DE60122928 T2 DE 60122928T2 DE 60122928 T DE60122928 T DE 60122928T DE 60122928 T DE60122928 T DE 60122928T DE 60122928 T2 DE60122928 T2 DE 60122928T2
- Authority
- DE
- Germany
- Prior art keywords
- benazepril
- amlodipine
- acceptable salt
- pharmaceutically acceptable
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title claims abstract description 87
- 229960004530 benazepril Drugs 0.000 title claims abstract description 79
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims description 18
- 230000001225 therapeutic effect Effects 0.000 title description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract description 91
- 229960000528 amlodipine Drugs 0.000 claims abstract description 86
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims abstract description 23
- 229960003619 benazepril hydrochloride Drugs 0.000 claims abstract description 21
- 239000012458 free base Substances 0.000 claims abstract description 20
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 19
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 206010020772 Hypertension Diseases 0.000 claims abstract description 14
- 229960004067 benazeprilat Drugs 0.000 claims abstract description 14
- 230000036772 blood pressure Effects 0.000 claims abstract description 12
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 8
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 7
- 208000019693 Lung disease Diseases 0.000 claims abstract description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 5
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims abstract description 5
- 201000009623 Myopathy Diseases 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 201000006370 kidney failure Diseases 0.000 claims abstract description 5
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 5
- 206010019233 Headaches Diseases 0.000 claims abstract description 4
- 208000021642 Muscular disease Diseases 0.000 claims abstract description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 4
- 231100000869 headache Toxicity 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 abstract description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229940127291 Calcium channel antagonist Drugs 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 8
- 229960004005 amlodipine besylate Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- 229940066469 amlodipine 5 mg Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 229940080288 lotrel Drugs 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229960000913 crospovidone Drugs 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 229910004298 SiO 2 Inorganic materials 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940066481 amlodipine 10 mg Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/US00/34246 | 2000-12-18 | ||
| PCT/US2000/034246 WO2002049645A1 (en) | 2000-12-18 | 2000-12-18 | Therapeutic combination of amlodipine and benazepril |
| PCT/US2001/048808 WO2002049646A1 (en) | 2000-12-18 | 2001-12-17 | Therapeutic combination of amlodipine and benazepril/benazeprilat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60122928D1 DE60122928D1 (de) | 2006-10-19 |
| DE60122928T2 true DE60122928T2 (de) | 2007-09-06 |
Family
ID=21742073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60122928T Revoked DE60122928T2 (de) | 2000-12-18 | 2001-12-17 | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP1365761A1 (https=) |
| JP (3) | JP2004516266A (https=) |
| KR (3) | KR20040007420A (https=) |
| CN (2) | CN1461218A (https=) |
| AT (1) | ATE338549T1 (https=) |
| AU (4) | AU2581601A (https=) |
| BR (2) | BR0017386A (https=) |
| CA (2) | CA2432638A1 (https=) |
| CY (1) | CY1106275T1 (https=) |
| CZ (2) | CZ20031678A3 (https=) |
| DE (1) | DE60122928T2 (https=) |
| DK (1) | DK1345607T3 (https=) |
| EC (1) | ECSP034658A (https=) |
| ES (1) | ES2272565T3 (https=) |
| HU (2) | HUP0302455A3 (https=) |
| IL (4) | IL156136A0 (https=) |
| MX (2) | MXPA03005462A (https=) |
| NO (2) | NO20032766L (https=) |
| NZ (1) | NZ526467A (https=) |
| PL (2) | PL362252A1 (https=) |
| PT (1) | PT1345607E (https=) |
| RU (1) | RU2292206C2 (https=) |
| SI (1) | SI1345607T1 (https=) |
| SK (2) | SK7652003A3 (https=) |
| WO (2) | WO2002049645A1 (https=) |
| ZA (1) | ZA200304514B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| MXPA05011371A (es) | 2003-04-25 | 2005-12-01 | Novacardia Inc | Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada. |
| TW200524591A (en) * | 2003-10-20 | 2005-08-01 | Novartis Ag | Use of organic compounds |
| WO2005074927A1 (en) * | 2004-02-09 | 2005-08-18 | Novartis Ag | Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension |
| WO2005079772A2 (en) * | 2004-02-18 | 2005-09-01 | Sepracor Inc. | Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| WO2006085208A2 (en) * | 2005-02-11 | 2006-08-17 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine and benazepril |
| WO2006092732A2 (en) * | 2005-03-04 | 2006-09-08 | Aurobindo Pharma Ltd | Stable solid dosage form of antihypertensive agent |
| AU2006224161A1 (en) | 2005-03-15 | 2006-09-21 | Lupin Limited | Pharmaceutical compositions of amlodipine and benazepril |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| WO2007040511A1 (en) * | 2005-09-28 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| DK1797885T3 (da) * | 2005-09-28 | 2008-07-14 | Teva Pharma | Stabil kombination af amlodipinbesylat og benazeprilhydrochlorid |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| IT1398168B1 (it) * | 2010-02-16 | 2013-02-14 | Chiesi Farma Spa | Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete. |
| EP2585051B2 (en) | 2010-06-23 | 2020-04-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| CN102389431A (zh) * | 2011-09-28 | 2012-03-28 | 济南龙华医药技术有限公司 | 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用 |
| AU2012357795B2 (en) | 2011-12-21 | 2017-04-06 | Elanco Tiergesundheit Ag | New combination |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| WO2014035707A1 (en) * | 2012-08-25 | 2014-03-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| CN108778334A (zh) * | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| UA124884C2 (uk) | 2016-11-16 | 2021-12-08 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Фармацевтичні склади |
| MA46866B1 (fr) | 2016-11-16 | 2021-11-30 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| JPH11500140A (ja) * | 1995-03-16 | 1999-01-06 | ファイザー・インコーポレーテッド | アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物 |
| TR199701121T1 (xx) * | 1995-04-07 | 1998-03-21 | Novartis Ag | Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri. |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
-
2000
- 2000-12-18 HU HU0302455A patent/HUP0302455A3/hu unknown
- 2000-12-18 AU AU2581601A patent/AU2581601A/xx active Pending
- 2000-12-18 AU AU2001225816A patent/AU2001225816B2/en not_active Ceased
- 2000-12-18 PL PL00362252A patent/PL362252A1/xx not_active Application Discontinuation
- 2000-12-18 JP JP2002550985A patent/JP2004516266A/ja active Pending
- 2000-12-18 EP EP00989288A patent/EP1365761A1/en not_active Withdrawn
- 2000-12-18 WO PCT/US2000/034246 patent/WO2002049645A1/en not_active Ceased
- 2000-12-18 CZ CZ20031678A patent/CZ20031678A3/cs unknown
- 2000-12-18 IL IL15613600A patent/IL156136A0/xx unknown
- 2000-12-18 SK SK765-2003A patent/SK7652003A3/sk not_active Application Discontinuation
- 2000-12-18 CA CA002432638A patent/CA2432638A1/en not_active Abandoned
- 2000-12-18 KR KR10-2003-7007578A patent/KR20040007420A/ko not_active Withdrawn
- 2000-12-18 CN CN00820080A patent/CN1461218A/zh active Pending
- 2000-12-18 MX MXPA03005462A patent/MXPA03005462A/es not_active Application Discontinuation
- 2000-12-18 BR BR0017386-0A patent/BR0017386A/pt not_active Application Discontinuation
-
2001
- 2001-12-17 AU AU3262002A patent/AU3262002A/xx active Pending
- 2001-12-17 AT AT01992150T patent/ATE338549T1/de active
- 2001-12-17 BR BR0116228-4A patent/BR0116228A/pt not_active IP Right Cessation
- 2001-12-17 DK DK01992150T patent/DK1345607T3/da active
- 2001-12-17 MX MXPA03005463A patent/MXPA03005463A/es active IP Right Grant
- 2001-12-17 WO PCT/US2001/048808 patent/WO2002049646A1/en not_active Ceased
- 2001-12-17 CZ CZ20031677A patent/CZ301424B6/cs not_active IP Right Cessation
- 2001-12-17 ES ES01992150T patent/ES2272565T3/es not_active Expired - Lifetime
- 2001-12-17 SK SK764-2003A patent/SK7642003A3/sk not_active Application Discontinuation
- 2001-12-17 EP EP06003150A patent/EP1674099A1/en not_active Withdrawn
- 2001-12-17 EP EP01992150A patent/EP1345607B1/en not_active Revoked
- 2001-12-17 PL PL01360989A patent/PL360989A1/xx not_active Application Discontinuation
- 2001-12-17 KR KR1020097004242A patent/KR20090033914A/ko not_active Ceased
- 2001-12-17 IL IL15626701A patent/IL156267A0/xx unknown
- 2001-12-17 CA CA002432282A patent/CA2432282A1/en not_active Abandoned
- 2001-12-17 SI SI200130662T patent/SI1345607T1/sl unknown
- 2001-12-17 RU RU2003121019/15A patent/RU2292206C2/ru not_active IP Right Cessation
- 2001-12-17 PT PT01992150T patent/PT1345607E/pt unknown
- 2001-12-17 AU AU2002232620A patent/AU2002232620B9/en not_active Ceased
- 2001-12-17 JP JP2002550986A patent/JP2004519440A/ja not_active Withdrawn
- 2001-12-17 NZ NZ526467A patent/NZ526467A/en unknown
- 2001-12-17 HU HU0302456A patent/HUP0302456A3/hu unknown
- 2001-12-17 CN CNA018208398A patent/CN1481241A/zh active Pending
- 2001-12-17 KR KR10-2003-7007754A patent/KR20030061840A/ko not_active Ceased
- 2001-12-17 DE DE60122928T patent/DE60122928T2/de not_active Revoked
-
2003
- 2003-06-10 ZA ZA200304514A patent/ZA200304514B/xx unknown
- 2003-06-17 EC EC2003004658A patent/ECSP034658A/es unknown
- 2003-06-17 NO NO20032766A patent/NO20032766L/no not_active Application Discontinuation
- 2003-06-17 NO NO20032765A patent/NO20032765L/no not_active Application Discontinuation
-
2006
- 2006-11-30 CY CY20061101728T patent/CY1106275T1/el unknown
-
2008
- 2008-04-10 IL IL190802A patent/IL190802A0/en unknown
- 2008-04-10 IL IL190801A patent/IL190801A0/en unknown
-
2009
- 2009-10-09 JP JP2009235225A patent/JP2010043111A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60122928T2 (de) | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat | |
| DE69922964T2 (de) | Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe | |
| DE69936992T2 (de) | Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker | |
| DE69730834T2 (de) | Verfahren zur herstellung von festen oralen dosierungsformen von valsartan | |
| DE60117295T2 (de) | Synergistische kombinationen mit einem renin-inhibitor für kardiovaskuläre erkrankungen | |
| DE60103556T3 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten | |
| DE60221691T2 (de) | Tamsulosin tabletten ohne nahrungsmitteleffekt | |
| DE60315795T2 (de) | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren | |
| DE60320652T2 (de) | Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittel | |
| DE69624910T2 (de) | Orale pharmazeutische dosierungsformen die einen protonenpumpeninhibitor und ein prokinetisches mittel enthalten | |
| DE60109903T2 (de) | Verwendung eines zentralen cannabinoid-rezeptor-antagonisten für die herstelling von arzneimitteln zur erleichterung der aufgabe des tabakverbrauchs | |
| DE60118008T2 (de) | Pharmazeutische zusammensetzungen mit amlodipinmaleat | |
| US6162802A (en) | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor | |
| DE10025946A1 (de) | Wirkstoffkombination | |
| DE212007000063U1 (de) | Feste Arzneiform von Olmesartan Medoxomil und Amlodipin | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| DE69929703T2 (de) | Neue orale formulierungen für 5-ht4 agonisten oder antagonisten | |
| DE3856555T2 (de) | Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption | |
| DE69801661T2 (de) | Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten | |
| DE602004012763T2 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| EP0224810B1 (de) | Antihypertensives Kombinationspräparat | |
| DE4124409B4 (de) | Pharmazeutische Zubereitungen | |
| DE19754082A1 (de) | Methode zur Bekämpfung der Fettleibigkeit | |
| DE69813083T2 (de) | Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen | |
| DE69625210T2 (de) | Nicorandil gegen angstneurosen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8331 | Complete revocation |